Pall Corporation announced that it has completed the acquisition of the BioSepra Process Division from Ciphergen Biosystems, Inc. The purchase price was $32 million, net of cash and debt. The BioSepra Process Division develops, manufactures and markets chromatography sorbents that greatly simplify protein purification for drug development and production.
Eric Krasnoff, Chairman and CEO of Pall Corporation, said, "The addition of this innovative, broad range of chromatography chemistries strengthens our ability to serve the needs of biotechnology customers. The marriage of BioSepra's capabilities and Pall's extensive existing product portfolio allows customers to benefit from a highly integrated 'Total Fluid Management' approach."
Pall plans to establish additional Process Proteomics Service Centers to assist customers in selecting and optimizing sorbents and membranes for the purification of proteins used in the production of therapeutic proteins and other bioprocess applications.
Pall and Ciphergen have also entered into a collaboration for process proteomics, based on the combination of Ciphergen's ProteinChip® technology and BioSepra's leading chromatography products.